Equity · Healthcare
AUPH
NASDAQAurinia Pharmaceuticals (AUPH)
The line runs 15.46 USD on 12 August through 16.63 USD on 9 November, on a scale from 15 to 18. Days the market did not trade hold the previous close, flat.
- Market cap
- 2.2B USD
- P/E (TTM)
- 7.3
- Revenue, year to Dec 2025
- 283.1M USD
- EPS, diluted, year to Dec 2025
- 2.07 USD
- 52-week range
- 13 USD – 19 USD
- Avg volume
- 61.7K
as of Nov 9, 2026
Have Aurinia Pharmaceuticals (AUPH) insiders bought or sold shares recently?
In the 90 days to 10 Nov 2026, Aurinia Pharmaceuticals insiders reported 2 open-market sales and no purchases (SEC Form 4); none has bought on the open market since 2 Jun 2026.
Form 4, 90 days to 10 Nov 2026, newest reported trade 10 Sep 2026
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 10 Sep 2026 | Robertson Stephen P.Chief Legal Officer | Sell | 11,939 | 190K USD |
| 21 Aug 2026 | Robertson Stephen P.Chief Legal Officer | Sell | 20,975 | 356K USD |
| Sold | 2 open-market sales | 32,914 | $546K |
Which funds hold Aurinia Pharmaceuticals (AUPH)?
9 of the 45 institutional funds we track reported a Aurinia Pharmaceuticals position for the quarter ended 30 Jun 2026 — a combined 171.0M USD; the latest of those filings landed 02 Sep 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| Two Sigma Investments | Held (±25%) | 3,467,514 | 58.8M USD | +1.1% |
| Marshall Wace | Held (±25%) | 2,044,007 | 34.7M USD | +9.0% |
| Renaissance Technologies | Held (±25%) | 1,548,035 | 26.3M USD | −7.0% |
| D. E. Shaw & Co. | Held (±25%) | 1,408,456 | 23.9M USD | −10.5% |
| AQR Capital Management | Held (±25%) | 948,751 | 16.1M USD | −0.0% |
| Millennium Management | Added | 244,302 | 4.1M USD | +108.5% |
| Citadel Advisors | Held (±25%) | 240,685 | 4.1M USD | −12.3% |
| Balyasny Asset Management | New position | 88,240 | 1.5M USD | |
| Man Group | Trimmed | 83,888 | 1.4M USD | −91.2% |
| Tudor Investment Corp | Exited |
What has been filed or recorded for Aurinia Pharmaceuticals (AUPH)?
The filings we hold for Aurinia Pharmaceuticals, newest first: 5 fails-to-deliver days, 4 quarterly earnings reports, 3 annual reports and 5 reported financial figures, the latest dated 08 Oct 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 08 Oct 2026 | Fails to deliver | Shares failed to deliver | 5,154 shares | 83K USD notional · 0.004% of shares out |
| 05 Oct 2026 | Fails to deliver | Shares failed to deliver | 241 shares | 4K USD notional · <0.001% of shares out |
| 02 Oct 2026 | Fails to deliver | Shares failed to deliver | 141 shares | 2K USD notional · <0.001% of shares out |
| 01 Oct 2026 | Fails to deliver | Shares failed to deliver | 8,000 shares | 130K USD notional · 0.006% of shares out |
| 30 Sep 2026 | Fails to deliver | Shares failed to deliver | 8,000 shares | 131K USD notional · 0.006% of shares out |
| 30 Sep 2026 | Quarterly earnings | Q3 2026 reported | EPS 0.23 USD | Revenue $84M |
| 30 Sep 2026 | Financials | Total assets | 825.7M USD | at period end |
| 30 Sep 2026 | Financials | Total equity | 657.5M USD | at period end |
| 30 Jun 2026 | Quarterly earnings | Q2 2026 reported | EPS 0.28 USD | Revenue $83M |
| 31 Mar 2026 | Quarterly earnings | Q1 2026 reported | EPS 0.25 USD | Revenue $78M |
| 31 Dec 2025 | Annual report | FY 2025 reported | EPS 1.53 USD | Revenue $77M |
| 31 Dec 2025 | Financials | Revenue | 283.1M USD | fiscal year |
| 31 Dec 2025 | Financials | Net income | 287.2M USD | fiscal year |
| 31 Dec 2025 | Financials | Diluted EPS | 2.07 USD | fiscal year |
| 30 Sep 2025 | Annual report | FY 2025 reported | EPS 0.23 USD | Revenue $73M |
| 30 Jun 2025 | Annual report | FY 2025 reported | EPS 0.16 USD | Revenue $70M |
| 31 Mar 2025 | Quarterly earnings | Q1 2025 reported | EPS 0.16 USD | Revenue $62M |
What do people ask about Aurinia Pharmaceuticals (AUPH)?
What did Aurinia Pharmaceuticals shares close at?16.63
Aurinia Pharmaceuticals closed at 16.63 USD on 9 Nov 2026, up 0.97% on the close before. That is the end-of-day price from Finazon, not a live quote.
What is Aurinia Pharmaceuticals’ market cap?2.2B
Aurinia Pharmaceuticals is worth 2.2B USD by market value as of 9 Nov 2026, which is the share price times the shares on issue from its SEC filings.
What is Aurinia Pharmaceuticals’ P/E ratio?7.3
Aurinia Pharmaceuticals has a price-to-earnings ratio of 7.3, as of 9 Nov 2026: the share price divided by what the company earned per share over the last four reported quarters. A higher number means the market pays more for each dollar of earnings.
What is Aurinia Pharmaceuticals’ revenue?283.1M
Aurinia Pharmaceuticals reported revenue of 283.1M USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings
Have Aurinia Pharmaceuticals insiders bought or sold shares recently?2 sales
In the 90 days to 10 Nov 2026, Aurinia Pharmaceuticals insiders reported 2 open-market sales and no purchases (SEC Form 4); none has bought on the open market since 2 Jun 2026. See Insiders
Which funds own Aurinia Pharmaceuticals?9 of 45
9 of the 45 funds we track reported a Aurinia Pharmaceuticals position for the quarter ended 30 Jun 2026, per their SEC Form 13F filings. The largest reported positions were Two Sigma Investments, Marshall Wace and Renaissance Technologies. See Funds
When did Aurinia Pharmaceuticals last report earnings?0.23
Aurinia Pharmaceuticals last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of 0.23 USD; no next date is announced in SEC filings yet. See Filings
Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
- TradingViewthe price chart widget, drawn by TradingView from their own data
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- SECSEC fails-to-deliver (CNS) data
- SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings